1 |
Robert C, Long GV, Brady B, et al. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. N Engl J Med 2015;372:320-30.
DOI
|
2 |
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:123-35.
DOI
|
3 |
Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus Docetaxel in Advanced Non squamous Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373:1627-39.
DOI
|
4 |
Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015;373:1803-13.
DOI
|
5 |
Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016;375:1856-67.
DOI
|
6 |
Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. N Engl J Med 2015;372:311-9.
DOI
|
7 |
Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicenter, single-arm, phase 2 trial. Lancet Oncol 2017;18(3):312-22.
DOI
|
8 |
Ministry of Food and Drug Safety. 2016 Medication approval report. Available from http://www.mfds.go.kr/index.do?mid=695&pageNo=1&seq=27418&cmd=v. Accessed April 13, 2017
|
9 |
Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol 2015;26: 2375-91.
|
10 |
American Society of Health-System Pharmacists. ASHP guidelines on medication-use evaluation. Am J Health-Syst Pharm 1996; 53:1953-5.
|
11 |
Opdivo(R) Intravenous injection (Nivolumab, recombinant). Ministry of Food and Drug Safety; 2016.5 Available from https://www.mfds.go.kr/. Accessed April 13, 2017.
|
12 |
Opdivo(R) [package insert]. Princeton, NJ: Bristol-Myers Squibb; Available from https://packageinserts.bms.com/pi/pi_opdivo.pdf. Accessed February 23, 2017.
|
13 |
Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Available from https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-_QuickReference_5x7.pdf. Accessed May 25, 2017.
|
14 |
Kumar V, Chaudhary N, Garg M, et al. Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Front Pharmacol 2017;8:311.
|
15 |
Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-65.
DOI
|
16 |
Agrawal S, Feng Y, Roy A, et al. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunother Cancer 2016; 4:72-82.
DOI
|
17 |
Christian G, Simon G, Richard E, et al. Hyponatremia as an unrecognized risk factor in non-small cell lung cancer (NSCLC) treatment with nivolumab. J Clin Oncol 2017;35:suppl; abstr e14526.
|
18 |
James L, Katy K, Alain P, et al. Relationship between liver metastases and PD1 blockade in melanoma. J Clin Oncol 2017; 35:suppl; abstr 3072.
|
19 |
Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016; 375:1823-33.
DOI
|